Screener
PTC Therapeutics PTCT Q3 2026 earnings
Reported October 29, 2026 · After market close
Revenue$357.8MBeat by $51.4M
EPS-$0.62Miss by $0.76
Revenue estimate$306.4M
EPS estimate$0.14
“Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did PTC Therapeutics report Q3 2026 earnings?
- PTC Therapeutics (PTCT) reported Q3 2026 earnings on October 29, 2026 after market close.
- What were PTC Therapeutics's Q3 2026 revenue and EPS?
- PTC Therapeutics reported revenue of $357.8M and eps of $-0.62 for Q3 2026.
- Did PTC Therapeutics beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $306.4M by $51.4M. EPS missed the consensus estimate of $0.14 by $0.76.
- How did PTC Therapeutics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 69.6% from $211.0M a year earlier.
- Where can I find PTC Therapeutics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-120200) and the 10-Q periodic report (0001104659-26-120223) directly on SEC EDGAR. The filing index links above go to sec.gov.
